Angelini Pharma and Quiver Bioscience Form Strategic Collaboration to Develop Therapies for Genetic Epilepsies
Tuesday, February 24, 2026
Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience, a company focused on discovering therapies for central nervous system (CNS) disorders, have entered a collaboration and licensing agreement to advance novel treatments for genetic epilepsies. The partnership combines Quiver’s drug discovery platform, data assets, and AI models with Angelini Pharma’s expertise in brain health and epilepsy drug development.
Under the multi-year agreement, Quiver will receive an upfront payment and support for specific research activities, as well as additional licensing fees for granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible for up to $120 million in milestone payments and additional royalties if Angelini selects drug targets identified through the collaboration.
The collaboration will focus on Developmental and Epileptic Encephalopathies (DEEs), a group of rare, genetically driven diseases affecting children worldwide. DEEs are associated with severe, treatment-resistant seizures and a range of neurodevelopmental symptoms. While some new treatments have been approved, there remains a significant unmet need for more effective therapies.
Quiver Bioscience’s platform employs human neuronal models with single-cell transcriptomic analysis, optical electrophysiology, and AI to accelerate the discovery of precision therapies. The goal of the partnership is to develop differentiated therapeutics capable of addressing multiple DEEs by linking functional neuronal changes to their underlying molecular causes.
This agreement builds on Angelini Pharma’s ongoing strategy to strengthen its global presence and expand its pipeline of innovative brain health medicines. It follows a series of strategic acquisitions and collaborations over the past two years aimed at enhancing the company’s portfolio in neuroscience.
Destum Partners acted as transaction advisor to Quiver Bioscience.
Source: businesswire.com
